Delving into the Latest Updates on Gunma University School of Medicine with Synapse

Overview

Tags

Immune System Diseases

Hemic and Lymphatic Diseases

Neoplasms

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Effects of massage (circulation-promoting stimulation) for relief of cold symptoms in women with cold sensitivity -pre and post comparative trial of self-hand massage and ear massage- - Effects of massage (circulation-promoting stimulation) for relief of cold symptoms in women with cold sensitivity -pre and post comparative trial of self-hand massage and ear massage-

Start Date15 Sep 2023

Sponsor / Collaborator

Gunma University School of Medicine

JPRN-UMIN000047331

/ SuspendedNot ApplicableIIT

Shared decision making on dialysis modality selection in Japan: a cross-sectional study - Shared decision making on dialysis modality selection in Japan: a cross-sectional study

Start Date16 May 2022

Sponsor / Collaborator

Gunma University School of Medicine

100 Clinical Results associated with Gunma University School of Medicine

Login to view more data

0 Patents (Medical) associated with Gunma University School of Medicine

Login to view more data

7,359

Literatures (Medical) associated with Gunma University School of Medicine

01 Dec 2025·Cancer Chemotherapy and Pharmacology

Variations in serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment

Article

Author: Yamamoto, Koujirou ; Morita, Jun ; Kogo, Mari ; Sato, Miki Takenaka ; Fukagai, Takashi ; Araki, Takuya ; Yashima, Hideaki ; Maeda, Yoshiko ; Ohbayashi, Masayuki ; Kohyama, Noriko ; Ishikawa, Yuya ; Ogawa, Yoshio

PURPOSEThe blood concentrations of some tyrosine kinase inhibitors are known to decrease with long-term administration. We evaluated the variability in the serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment.METHODSThis study prospectively recruited patients who received sunitinib for metastatic renal cell carcinoma at the Showa University Hospital between March 2020 and January 2022. Bivariate correlations between the serum concentration/dose (C/D) ratios of sunitinib and its metabolites (i.e., N-desethyl sunitinib and sunitinib N-oxide) and treatment duration were evaluated using Pearson's correlation coefficient.RESULTSSeven patients were enrolled, and 79 blood samples were collected. Among six patients who received sunitinib for > 1 year, three showed a decreasing trend in the C/D ratio of sunitinib (Pt1: r = -0.608, p = 0.047; Pt2: r = -0.555, p = 0.077; Pt6: r = -0.590, p = 0.073). In these patients, the median annual decrease in the C/D ratio of sunitinib was 55.8% (26.5-63.2%). Additionally, two of the three patients also showed a decrease in the C/D ratio of N-desethyl sunitinib. The ratio of N-desethyl sunitinib/sunitinib concentration at baseline and the end of follow-up was similar between the C/D-decreased and C/D-non-decreased groups.CONCLUSIONThis study showed that the C/D ratio of sunitinib decreased by half over time in half of the patients who received long-term sunitinib treatment despite continuing the same dose. Therefore, serum concentrations of sunitinib and its metabolites should be monitored periodically in patients receiving long-term treatment to prevent decrease in serum sunitinib concentrations.

01 Mar 2025·International Journal of Cardiology

Heart failure with preserved ejection fraction in atrial functional mitral regurgitation – Insight from the REVEAL-AFMR

Article

Author: Obokata, Masaru ; Okada, Taiji ; Sato, Yukio ; Kaneko, Tomohiro ; Harada, Tomonari ; Abe, Yukio ; Amano, Masashi ; Morita, Kojiro ; Machino-Ohtsuka, Tomoko ; Kagami, Kazuki ; Kagiyama, Nobuyuki ; Ohno, Yohei ; Ishii, Hideki ; Sato, Kimi

BACKGROUNDAtrial functional mitral regurgitation (AFMR) and heart failure with a preserved ejection fraction (HFpEF) often coexist. However, the clinical impact of HFpEF in patients with AFMR has not been well characterized. This study aimed to determine clinical outcomes and response to mitral valve (MV) intervention or rhythm control therapy in patients with HFpEF and moderate AFMR (HFpEF-AFMR).METHODSThis was a post-hoc analysis of the REVEAL-AFMR, a retrospective observational study involving patients with ≥ moderate AFMR. After excluding patients with severe MR, the presence of HFpEF was defined by the Universal definition.RESULTSOf 438 patients with moderate AFMR, 352 met the criteria of HFpEF (prevalence: 80 %). Compared to non-HFpEF-AFMR (n = 86), patients with HFpEF-AFMR were older and had greater symptom burden and a higher prevalence of severe tricuspid regurgitation (19 %). During a median follow-up of 33.2 months, a composite outcome of all-cause mortality or HF hospitalization occurred in 130 patients. Patients with HFpEF-AFMR had a 3.6-fold increased risk of the composite outcome compared to non-HFpEF-AFMR. While MV intervention was not associated with outcomes in HFpEF-AFMR, concomitant tricuspid valve (TV) procedures were associated with a better outcome than isolated MV intervention (HR 0.15, 95 %CI 0.04-0.54, p = 0.009). Catheter or surgical rhythm control showed a favorable outcome in HFpEF-AFMR and atrial fibrillation (HR 0.38, 95 %CI 0.17-0.87, p = 0.008).CONCLUSIONHFpEF was substantially common in moderate AFMR and was associated with worse clinical outcomes. Simultaneous MV and TV intervention procedures or rhythm control therapy were associated with better clinical outcomes in HFpEF-AFMR.

15 Jan 2025·Internal Medicine

Concurrent Amyotrophic Lateral Sclerosis and Huntington's Disease

Article

Author: Nagashima, Kazuaki ; Takahashi, Ryoma ; Ikeda, Yoshio ; Furuta, Minori

Huntington's disease (HD) is a dominantly inherited neurological disorder characterized by chorea, psychiatric symptoms, and cognitive decline but typically lacks muscular atrophy and weakness. We herein report a case of genetically confirmed HD showing progressive systemic weakness with findings of upper and lower motor neuron involvement due to amyotrophic lateral sclerosis (ALS). The current patient and the previously reported cases with complications of HD and ALS indicate that cytosine-adenine-guanine (CAG) repeat expansion in the huntingtin gene might have a pathogenic role in causing the two neurological disorders.

100 Deals associated with Gunma University School of Medicine

Login to view more data

100 Translational Medicine associated with Gunma University School of Medicine

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Other

Login to view more data